Beta-blockers (All routes except ocular) (versus unexposed) updated on 12-17-2024

Neonatal death (< 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S14051
R55689		 Xiang - Labetalol, 2020 Neonatal mortality during pregnancy (anytime or not specified) randomized controlled trial unexposed, sick Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication 1.68 [0.59;4.78] C 10/124   6/121 16 124
ref
S14071
R55398		 Tanaka - Beta-blockers, 2016 Neonatal deaths during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 2.24 [0.04;114.50] C 0/45   0/100 0 45
ref
S14041
R55418		 Lieberman - Propranolol, 1978 Neonatal death during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 0.29 [0.01;6.93] C 0/9   2/15 2 9
ref
Total 3 studies 1.45 [0.56;3.81] 18 178
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Xiang - Labetalol, 2020Xiang - Labetalol, 2020 1.68[0.59; 4.78]1612485%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Tanaka - Beta-blockers, 2016Tanaka - Beta-blockers, 2016 2.24[0.04; 114.50]0456%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Lieberman - Propranolol, 1978Lieberman - Propranolol, 1978 0.29[0.01; 6.93]299%ROB confusion: criticalROB selection: unclearROB classification: unclearROB missing: lowROB mesure: unclearROB reporting: moderate Total (3 studies) I2 = 0% 1.45[0.56; 3.81]181780.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.65[0.06; 7.65]2540%NATanaka - Beta-blockers, 2016 Lieberman - Propranolol, 1978 2 case control studiescase control studies 0 RCTRCT 1.68[0.59; 4.78]16124 -NAXiang - Labetalol, 2020 1 Type of controls unexposed, sickunexposed, sick 1.45[0.56; 3.81]181780%NAXiang - Labetalol, 2020 Tanaka - Beta-blockers, 2016 Lieberman - Propranolol, 1978 3 Tags Adjustment   - No  - No 0.65[0.06; 7.65]2540%NATanaka - Beta-blockers, 2016 Lieberman - Propranolol, 1978 2   - Randomisation  - Randomisation 1.68[0.59; 4.78]16124 -NAXiang - Labetalol, 2020 1 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 0.29[0.01; 6.93]29 -NALieberman - Propranolol, 1978 1   - Only cardiac indications other than ...  - Only cardiac indications other than hypertension (long QT syndrome, structural heart disease, ...) 2.24[0.04; 114.50]-45 -NATanaka - Beta-blockers, 2016 1   - Only chronic hypertension indication  - Only chronic hypertension indication 1.68[0.59; 4.78]16124 -NAXiang - Labetalol, 2020 1 All studiesAll studies 1.45[0.56; 3.81]181780%NAXiang - Labetalol, 2020 Tanaka - Beta-blockers, 2016 Lieberman - Propranolol, 1978 30.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.45[0.56; 3.81]181780%NAXiang - Labetalol, 2020 Tanaka - Beta-blockers, 2016 Lieberman - Propranolol, 1978 30.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Shekhar (Intravenous labetalol) - GESTATIONAL ...Shekhar (Intravenous labetalol) - GESTATIONAL HYPERTENSION (Neonatal death) 3.70[1.15; 11.10]0%-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT4 Sridharan (Labetalol) (Neonatal death (versus ...Sridharan (Labetalol) (Neonatal death (versus hydralazine)) 0.80[0.20; 3.60]NA-Eexposed to other treatment, sickAnyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.45[0.56; 3.81]0%178----Xiang - Labetalol, 2020 Tanaka - Beta-blockers, 2016 Lieberman - Propranolol, 1978 30.510.01.0